Business
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
SOUTH SAN FRANCISCO, Calif., February 20, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference.
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/e0424b4091a3b41edf08dcbe85784a69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8wF3lx1ZYvja4xpqMqOImQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e0424b4091a3b41edf08dcbe85784a69","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_u2v9PcCkR_LC5KhMfITdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e0424b4091a3b41edf08dcbe85784a69","width":1200,"height":325}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., February 20, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference.","length":345,"tagName":"p"},{"type":"text","content":"Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time. A webcast will be accessible through the "Events" page in the "Investors" section of the Company’s website at www.Vistagen.com. A replay of the webcast will be archived and available following the event.","length":373,"tagName":"p"},{"type":"text","content":"About Vistagen","length":14,"tagName":"p"},{"type":"text","content":"Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal therapies called pherines.","length":328,"tagName":"p"},{"type":"text","content":"Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, which activate olfactory bulb-to-brain neurocircuits without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits and differentiated safety. Vistagen’s neuroscience pipeline also includes an oral p...